EGFR and non-small cell lung carcinoma: Afatinib is indicated for patients with NSCLC and exon 19 deletions (Ex19del), the L858R substitution mutation or other uncommon sensitizing EGFR mutations; it is also indicated for patients with squamous cell carcinoma of the lung after failure of first-line chemotherapy (48, 113).